Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press24610.17650/1726-9776-2011-7-3-118-121PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫRADICAL PROSTATECTOMY WITH EXTENDED PELVIC LYMPHADENECTOMY AND ADJUVANT HORMONAL THERAPY IN PATIENTS WITH LYMPHOGENIC DISSEMINATED PROSTATE CANCERРАДИКАЛЬНАЯ ПРОСТАТЭКТОМИЯ С РАСШИРЕННОЙ ТАЗОВОЙ ЛИМФАДЕНЭКТОМИЕЙ И АДЪЮВАНТНАЯ ГОРМОНАЛЬНАЯ ТЕРАПИЯ У БОЛЬНЫХ ЛИМФОГЕННО-ДИССЕМИНИРОВАННЫМ РАКОМ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫAlekseevB. Ya.АлексеевБ. Я.
Russian Federation
byalekseev@mail.ruNyushkoK. M.НюшкоК. М.
Russian Federation
byalekseev@mail.ruP.A. Herzen Moscow Oncology Research Institute, MoscowМНИОИ им. П.А. Герцена, Москва30092011731181210308201403082014https://oncourology.abvpress.ru/oncur/article/view/246

The main radical treatments for patients with prostate cancer (PC) are radical prostatectomy (RPE) and radiotherapy. At the same time pelvic lymphadenectomy (PLAE) in patients with PC is an important diagnostic step during both surgical and radiation treatments. The main goal of PLAE is to evaluate the pelvic lymph nodes. The paper gives the data of a number of trials of the efficiency of RPE with extended PLAE and adjuvant hormonal therapy.

Основными методами радикального лечения больных раком предстательной железы (РПЖ) являются радикальная простатэктомия (РПЭ) и лучевая терапия (ЛТ). При этом тазовая лимфаденэктомия (ТЛАЭ) у больных РПЖ — важный диагностический этап как при выполнении хирургического, так и лучевого лечения. Основная цель ТЛАЭ заключается в оценке состояния тазовых лимфатических узлов (ЛУ). В статье приводятся данные ряда исследований, посвященных изучению эффективности РПЭ с расширенной ТЛАЭ и адъювантной гормональной терапии.

prostate cancerradical prostatectomyhormonal therapylymph nodes, survivalрак предстательной железырадикальная простатэктомиягормональная терапиялимфатические узлывыживаемость1. Чиссов В.И., Старинский В.В. (ред.) Состояние онкологической помощи населению России в 2010 году. М., 2011.Чиссов В.И., Старинский В.В. (ред.) Состояние онкологической помощи населению России в 2010 году. М., 2011.2. Ilic D., O’Connor D., Green S., Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 2007;18(3):279−85.Ilic D., O’Connor D., Green S., Wilt T. Screening for prostate cancer: a Cochrane systematic review. Cancer Causes Control 2007;18(3):279−85.3. Bartsch G., Horninger W., Klocker H. et al. Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58(3):417−24.Bartsch G., Horninger W., Klocker H. et al. Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 2001;58(3):417−24.4. Andriole G.L., Crawford E.D., Grubb R.L. 3rd, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 Mar 26;360(13):1310−9.Andriole G.L., Crawford E.D., Grubb R.L. 3rd, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009 Mar 26;360(13):1310−9.5. Schröder F.H., Hugosson J., Roobol M.J. et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13):1320−8.Schröder F.H., Hugosson J., Roobol M.J. et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13):1320−8.6. Briganti A., Chun F.K., Salonia A. et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 2007;69(1):147−51.Briganti A., Chun F.K., Salonia A. et al. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. Urology 2007;69(1):147−51.7. Malmström P.U. Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005; 44(6):593−8.Malmström P.U. Lymph node staging in prostatic carcinoma revisited. Acta Oncol 2005; 44(6):593−8.8. Hsu C.-Y., Joniau S., Oyen R. et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single institutional experience. Eur Urol 2007;51:121−9.Hsu C.-Y., Joniau S., Oyen R. et al. Outcome of surgery for clinical unilateral T3a prostate cancer: a single institutional experience. Eur Urol 2007;51:121−9.9. Freedland S.J., Partin A.W., Humphreys E.B. et al. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109:1273−8.Freedland S.J., Partin A.W., Humphreys E.B. et al. Radical prostatectomy for clinical stage T3a disease. Cancer 2007;109:1273−8.10. Schroder F.H., Kurth K.H., Fossa S.D. et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organization for the Research and Treatment of Cancer 30846 — a phase III study. J Urol 2004;172:923−7.Schroder F.H., Kurth K.H., Fossa S.D. et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organization for the Research and Treatment of Cancer 30846 — a phase III study. J Urol 2004;172:923−7.11. Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54:344−52.Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54:344−52.12. Cheng L., Zincke H., Blute M.L. et al. Risk of prostate carcinoma death in patients with lymph node metastases. Cancer 2001;91:66−73.Cheng L., Zincke H., Blute M.L. et al. Risk of prostate carcinoma death in patients with lymph node metastases. Cancer 2001;91:66−73.13. Bader P., Burkhard F.C., Markwalder R. et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849−54.Bader P., Burkhard F.C., Markwalder R. et al. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol 2003;169:849−54.14. Briganti A., Capitanio U., Chun F.K.-H. et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008; 54:794−804.Briganti A., Capitanio U., Chun F.K.-H. et al. Impact of surgical volume on the rate of lymph node metastases in patients undergoing radical prostatectomy and extended pelvic lymph node dissection for clinically localized prostate cancer. Eur Urol 2008; 54:794−804.15. Daneshmand S., Quek M.L., Stein J.P. et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252−5.Daneshmand S., Quek M.L., Stein J.P. et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252−5.16. Engel J., Bastian P.J., Baur H. et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754−761.Engel J., Bastian P.J., Baur H. et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur Urol 2010;57:754−761.17. Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with nodepositive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472−9.Messing E.M., Manola J., Yao J. et al. Immediate versus deferred androgen deprivation treatment in patients with nodepositive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006;7(6):472−9.18. Ghavamian R., Bergstralh E.J., Blute M.L. et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161:1223−8.Ghavamian R., Bergstralh E.J., Blute M.L. et al. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol 1999;161:1223−8.19. Burkhard F.C., Schumacher M.C., Studer U.E. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006;3(9):454−5.Burkhard F.C., Schumacher M.C., Studer U.E. An extended pelvic lymph-node dissection should be performed in most patients if radical prostatectomy is truly indicated. Nat Clin Pract Urol 2006;3(9):454−5.20. Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006;50(2):272−9.Schumacher M.C., Burkhard F.C., Thalmann G.N. et al. Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol 2006;50(2):272−9.